INAB IN8BIO INC

IN8bio to Present at Biotech Showcase 2025 in San Francisco

IN8bio to Present at Biotech Showcase 2025 in San Francisco

NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate at Biotech Showcase 2025 on a panel on Monday, January 13, 2025, and present on Tuesday, January 14, 2025, at the Hilton San Francisco Union Square Hotel in San Francisco, CA. Details for the event are provided below.

Biotech Showcase, January 13 - 15, 2025

Panel: The Battle Against Cancer: The Armamentarium Keeps Expanding

  • Date: Monday, January 13, 2025
  • Time: 8:00 AM PT
  • Track: Yosemite C (Ballroom Level)

Corporate presentation

  • Date: Tuesday, January 14, 2025
  • Time: 2:00 PM PT
  • Track: Yosemite A (Ballroom Level)

  • Live webcast: 

Interested parties can register to attend the event here: /biotech-showcase/registration-options/

Additionally, IN8bio management will be in San Francisco from January 13-16, 2025, during the 43rd Annual J.P. Morgan Health Care Conference and will be available for meetings with investors. Individuals interested in meeting with IN8bio management can contact .

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-100, is focused on AML evaluating haplo-matched allogeneic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma. For more information about IN8bio, visit .

Investors & Company Contacts

Glenn Schulman, PharmD, MPH

203.494.7411

IN8bio, Inc.

Patrick McCall

646.933.5603

Media Contact

Kimberly Ha

KKH Advisors

917.291.5744



EN
06/01/2025

Underlying

INABIN8BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IN8BIO INC

 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio to Present at TD Cowen 46th Annual Health Care Conference

IN8bio to Present at TD Cowen 46th Annual Health Care Conference NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, at 9:50 am ET. William Ho will be giving a company presentation highlighting IN8bio’s latest achievements and upcoming milestones. The conference, to be held March 2-4, 2026, in Boston, wil...

February 24, 2026 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating ...

IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the promotion of Kate Rochlin, Ph.D., to President and Chief Operating Officer, effective immediately. Dr. Rochlin has served as IN8bio’s Chief Operating Officer since December 2021, following her tenure as Vice President and Associate Vice President of Operations and Innovation beg...

February 9, 2026 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio to Present at Upcoming Investor and Scientific Conferences in F...

IN8bio to Present at Upcoming Investor and Scientific Conferences in February NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting the following investor and scientific conferences in February. Conference participation details are as follows: Noble Emerging Growth Virtual Equity ConferenceDate: Thursday, February 5, 2026Time: 3:00 p.m. ETLocation: Virtual IO360° Conferenc...

February 3, 2026 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and D...

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma Repeat-doses of DeltEx™ Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to only 6.6 months (+97%) in a control cohort treated with the standard-of-care (SOC) Stupp protocolMedian overall survival (mOS) continues to climb, currently at 17.2+ months as of December 31, 2025, with several patients who remain progression-free for multiple years (1.4 – 4.6 years) compared to onl...

January 12, 2026 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Announces Pricing of Private Placement of up to $40.2 Million t...

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager $20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta (“γδ”) T cell engager through an Investigational New Drug (“IND”) application Financing led by Coastlands Capital with participation from new and existing biotechnology investors Initial proceeds extend cash runway into the first half of 2027 NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (“IN8Bio” or the “Company”) (Nasdaq: INAB), a clinical-stage...

December 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch